Abstract 1118P
Background
Many patients with BRAF+ metastatic melanoma (MM) experience tumor progression during first-line (1L) immunotherapy (IO). This real-world study evaluated the characteristics, treatment patterns, and outcomes among BRAF+ MM patients who experienced disease progression while on 1L IO.
Methods
This retrospective cohort study used Flatiron Health data from 1/1/2014 to 9/30/2021. Included patients were age ≥18 years with BRAF+ MM and were 1L IO-refractory, defined as having documented disease progression within 6 months of 1L IO initiation. Therapy use post-progression was defined as 2L, regardless of whether it was a new therapy or the same as 1L. Patient characteristics and treatment patterns were evaluated descriptively. The Kaplan-Meier method was used to describe overall survival (OS) and time to progression or death (TTPD) in patients who continued to receive IO (2L IO) and those who switched to targeted therapy (2L TT), from the start of 2L therapy.
Results
A total of 325 patients (mean age 60 years, 65% male) were included. Median time from 1L IO initiation to first disease progression was 64 days. Post-progression, 157 patients (48%) were treated with 2L IO within a median of 0 days and 83 (26%) initiated 2L TT within a median of 13 days. The median duration of 2L therapy for patients treated with 2L IO and 2L TT was 127 vs 182 days, respectively. Patients on 2L IO had improved median OS compared to those who received 2L TT (27.2 vs 10.5 months; p<0.0001) as well as improved time to next progression at 1 (32 vs 11%) and 2 years (23 vs 2%). Median TTPD was similar for patients treated with 2L IO and 2L TT (4.1 vs 4.8 months; p=0.078), despite patients receiving 2L TT having evidence of more severe disease (higher ECOG, elevated lactate dehydrogenase, and more liver metastases).
Conclusions
Outcomes among patients with 1L IO-refractory BRAF+ MM are poor and many patients progress on 2L therapy. While 2L IO appeared to lead to more durable treatment responses for some patients, 2L TT was associated with a similar TTPD despite patients having more severe disease. Earlier use of TT (i.e., 1L TT+IO combinations) should be considered for this group with especially poor prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novartis Pharmaceuticals Corporation.
Funding
Novartis Pharmaceuticals Corporation.
Disclosure
T. Truong, S. Chandra, Z. Eroglu: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis. L. Connolly, R. Shah: Financial Interests, Personal, Full or part-time Employment: Novartis. C. Byrne, J. Tang: Financial Interests, Institutional, Speaker, Consultant, Advisor: Novartis.
Resources from the same session
1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Presenter: Jorge Bartolome
Session: Poster session 13
1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Presenter: Marin Golcic
Session: Poster session 13
1173P - NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma
Presenter: Yu Xu
Session: Poster session 13
1174P - Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Presenter: Eva Muñoz Couselo
Session: Poster session 13
1175P - Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
Presenter: Judith Lijnsvelt
Session: Poster session 13
1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Presenter: Anna Czarnecka
Session: Poster session 13
1177P - Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
Presenter: Ralf Gutzmer
Session: Poster session 13
1178P - Melanoma incidence rises for pediatrics: 15-year nationwide retrospective cohort study in Korea (2004-2019)
Presenter: Jisu Oh
Session: Poster session 13
1179P - The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients
Presenter: Amr Ehab El-Qushayri
Session: Poster session 13